We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid POC Blood Ammonia Detector Could Dramatically Decrease Processing Times from Hours to Minutes

By LabMedica International staff writers
Posted on 14 Mar 2022

Hyperammonemia (elevated blood ammonia) frequently occurs secondary to organic acidemia and is responsible for a large portion of brain damage and death in these patients. More...

Timely intervention to reduce ammonia levels is essential to improve neurodevelopmental outcomes, but diagnosing hyperammonemic infants before an acute crisis is extremely challenging with the standard clinical ammonia test which can take hours. A new point-of-care ammonia testing device works within minutes using just a drop of blood from an earlobe or finger prick, similar to how a glucometer measures blood sugar.

Aza Technology Inc. has developed a Rapid Ammonia Monitoring Device (AMD) intended for the quantitative determination of ammonia in whole blood, which enables the early detection of hyperammonemia that is critical to prevent irreversible neurological damage, coma, and death. The AMD can be lifesaving as it aims to dramatically decrease blood ammonia processing times from hours to minutes. The AMD has been granted Breakthrough Device designation from the Food and Drug Administration (FDA) for point-of-care measurement of ammonia for use in pediatric patients, including neonates as an aid in the diagnosis of inborn errors of metabolism. Aza Technology has hired Elbit Systems of America, LLC’s KMC Systems, Inc. (Merrimack, NH, USA) to gain FDA approval for its rapid blood ammonia detector for use in both adult and pediatric patients, as well as for manufacturing of the device and its consumables.

Hyperammonemia can strike at any age and timely diagnosis is limited by the current process and testing technology. The standard assay requires intravenous access for at least 1 mL of blood and must be performed in specialized clinical labs. Obtaining samples requires an extremely skilled phlebotomist since accurate values can only be obtained from draws performed without a tourniquet, and patient distress or a slow-flowing venipuncture can contribute to inaccuracies. Additionally, blood is unstable and releases ammonia over time, and therefore samples must be transported on ice and processed rapidly to avoid false elevations.

Aza Technology achieved a breakthrough with the recognition that ammonia could be measured in small volumes of whole blood simply by alkalizing the blood sample and monitoring the concentration of ammonia released from the sample. The company has developed a handheld device that produces accurate ammonia readings in less than a minute from a single drop of blood. The device is as easy to use as a blood glucose meter, and because it detects ammonia in the gas phase, typical interferents in the blood that can cause inaccurate readings with the conventional plasma ammonia test do not influence its results. Furthermore, the immediate readout eliminates complications from sample handling and permits the immediate evaluation of the patient’s status with respect to their ammonia treatment regimen.

“Between hospital and/or clinic visits, parents and caregivers are challenged to know ammonia levels and when their level would require immediate attention or action,” said Kathy Stagni, Executive Director of the Organic Acidemia Association. “The availability of a rapid point-of-care ammonia device, such as the AMD, with the capability of monitoring blood ammonia, will be a game-changer for the patient and the caregivers.”

Related Links:
KMC Systems, Inc.


New
Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Alcohol Testing Device
Dräger Alcotest 7000
New
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)

Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. Yet, current tools used... Read more

Immunology

view channel
Image: The new technology could predict who will benefit from immunotherapy (Photo courtesy of Max Delbrück Center)

New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response

A healthy immune system depends on complex communication between specialized cell types that detect, alert, and eliminate harmful threats. When these immune signaling pathways break down, the result can... Read more

Microbiology

view channel
Image: MycoMEIA Aspergillus Assay is the first FDA-cleared urine-based test for invasive aspergillosis (Photo courtesy of Pearl Diagnostics)

Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases.... Read more

Industry

view channel
Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)

Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has entered into an agreement with Mdxhealth SA (Irvine, CA, USA), which will acquire its Exosome Diagnostics Inc. (Waltham, MA, US) business, including the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.